(Q70359623)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

title

Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

main subject

phase I clinical trial

1 reference

1 reference

C L Vogel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

E Gorowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

E Davila

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

M Eisenberger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

J Kosinski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

R P Agarwal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

N Savaraj

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

publication date

1 January 1987

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

10 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

page(s)

187-198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3115912%20AND%20SRC:MED&resulttype=core&format=json

Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).

10 October 2019

cites work

1 reference

12 December 2020

Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine

1 reference

12 December 2020

Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil

1 reference

12 December 2020

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943)

1 reference

12 December 2020

Treatment of Kaposi's sarcoma with ICRF-159 (NSC-129943)

1 reference

12 December 2020

Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group

1 reference

12 December 2020

Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters

1 reference

12 December 2020

Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung

1 reference

12 December 2020

Acute myelomonocytic leukaemia after razoxane therapy

1 reference

12 December 2020

Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma

1 reference

12 December 2020

ICRF-187 in clinical oncology.

1 reference

12 December 2020

Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy

1 reference

12 December 2020

Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults

1 reference

12 December 2020

Phase I trial of ICRF-187 by 48-hour continuous infusion.

1 reference

12 December 2020

Antitumour Activity in a Series of bisDiketopiperazines

1 reference

12 December 2020

Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant Characteristic

1 reference

12 December 2020

Influence of ICRF 159 and triton WR 1339 on metastases of a rat epithelioma

1 reference

12 December 2020

Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors

1 reference

12 December 2020

The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo

1 reference

12 December 2020

Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU

1 reference

12 December 2020

Phase II study of ICRF-159 in refractory metastatic breast cancer

1 reference

12 December 2020

Preclinical toxicologic evaluation of ICRF-187 in dogs

1 reference

12 December 2020

Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma

1 reference

12 December 2020

Determination of (±)‐1,2‐Bis(3,5‐dioxopiperazinyl) propane Plasma Levels in Rats, Rabbits, and Humans by GLC and Mass Fragmentography

1 reference

12 December 2020

The bioavailability in man of ICRF-159 a new oral antineoplastic agent

1 reference

12 December 2020

Phase I study of ICRF-187 using a daily for 3 days schedule

1 reference

12 December 2020

Phase II study of ICRF-159 in non-Hodgkin's lymphomas

1 reference

12 December 2020

Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy

1 reference

12 December 2020

Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial

1 reference

12 December 2020

ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study

1 reference

12 December 2020

Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy

1 reference

12 December 2020

Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma

1 reference

12 December 2020

Treatment of blast cell crisis of chronic myeloid leukemia with ICRF-159 (razoxane)

1 reference

12 December 2020

Phase II trial of ICRF-187 in non-small cell lung cancer

1 reference

12 December 2020

Mode of Action of the Cytostatic Agent ‘ICRF 159’

1 reference

12 December 2020

Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159

1 reference

12 December 2020

Biochemical studies on growth-inhibitory bisdioxopiperazines. I. Effect on dna, rna and protein synthesis in mouse-embryo fibroblasts

1 reference

12 December 2020

Razoxane and leukaemia

1 reference

12 December 2020

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

1 reference

12 December 2020

Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma

1 reference

12 December 2020

Effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma

1 reference

12 December 2020

The effect of (±) 1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF 159) on liver metastases from a hamster lymphoma

1 reference

12 December 2020

Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas

1 reference

12 December 2020

Prevention of the Cardiotoxic Effects of Adriamycin and Daunomycin in the Isolated Dog Heart

1 reference

12 December 2020

Control of Malignant Metastases by ICRF 159

1 reference

12 December 2020

Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy

1 reference

12 December 2020

Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients

1 reference

12 December 2020

Epitheliomas in patients receiving razoxane therapy for psoriasis

1 reference

12 December 2020

Limited activity of ICRF-159 in advanced acute leukemia

1 reference

12 December 2020

Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943)

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00203545

0 references

1 reference